Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 8 studies | 25% ± 5% | |
epithelial cell | 6 studies | 35% ± 12% | |
pancreatic A cell | 4 studies | 42% ± 10% | |
GABAergic neuron | 4 studies | 29% ± 6% | |
endothelial cell of artery | 4 studies | 17% ± 2% | |
type B pancreatic cell | 3 studies | 40% ± 13% | |
non-classical monocyte | 3 studies | 22% ± 4% | |
neuron | 3 studies | 26% ± 12% | |
retinal ganglion cell | 3 studies | 49% ± 27% | |
extravillous trophoblast | 3 studies | 49% ± 13% | |
retinal cone cell | 3 studies | 34% ± 11% | |
ciliated cell | 3 studies | 29% ± 7% | |
endothelial cell of vascular tree | 3 studies | 19% ± 2% | |
glutamatergic neuron | 3 studies | 39% ± 12% | |
dendritic cell | 3 studies | 23% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1029.07 | 1445 / 1445 | 100% | 38.58 | 183 / 183 |
ovary | 100% | 1108.92 | 180 / 180 | 100% | 31.75 | 430 / 430 |
brain | 100% | 2493.23 | 2639 / 2642 | 100% | 29.61 | 705 / 705 |
stomach | 100% | 1306.05 | 359 / 359 | 100% | 46.02 | 285 / 286 |
intestine | 100% | 1431.14 | 966 / 966 | 99% | 44.67 | 524 / 527 |
prostate | 100% | 972.63 | 244 / 245 | 100% | 32.47 | 501 / 502 |
thymus | 100% | 1149.93 | 653 / 653 | 99% | 32.62 | 601 / 605 |
lung | 99% | 980.18 | 575 / 578 | 99% | 29.94 | 1149 / 1155 |
breast | 100% | 1061.09 | 459 / 459 | 99% | 25.85 | 1106 / 1118 |
pancreas | 100% | 880.50 | 328 / 328 | 98% | 31.17 | 175 / 178 |
kidney | 100% | 1749.03 | 89 / 89 | 98% | 33.61 | 882 / 901 |
adrenal gland | 100% | 1285.07 | 258 / 258 | 98% | 47.25 | 225 / 230 |
liver | 100% | 1201.74 | 226 / 226 | 98% | 21.00 | 396 / 406 |
uterus | 99% | 954.06 | 169 / 170 | 97% | 23.36 | 443 / 459 |
bladder | 100% | 797.24 | 21 / 21 | 92% | 22.94 | 462 / 504 |
skin | 93% | 773.16 | 1683 / 1809 | 88% | 15.53 | 413 / 472 |
spleen | 100% | 789.31 | 241 / 241 | 0% | 0 | 0 / 0 |
adipose | 100% | 1113.87 | 1203 / 1204 | 0% | 0 | 0 / 0 |
muscle | 100% | 897.47 | 801 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 940.05 | 1328 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 1072.12 | 848 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 14.19 | 44 / 45 |
lymph node | 0% | 0 | 0 / 0 | 93% | 13.12 | 27 / 29 |
eye | 0% | 0 | 0 / 0 | 55% | 6.56 | 44 / 80 |
peripheral blood | 50% | 254.92 | 467 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006915 | Biological process | apoptotic process |
GO_0009231 | Biological process | riboflavin biosynthetic process |
GO_0009398 | Biological process | FMN biosynthetic process |
GO_0072593 | Biological process | reactive oxygen species metabolic process |
GO_0033864 | Biological process | positive regulation of NAD(P)H oxidase activity |
GO_0072388 | Biological process | flavin adenine dinucleotide biosynthetic process |
GO_0006771 | Biological process | riboflavin metabolic process |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005739 | Cellular component | mitochondrion |
GO_0008531 | Molecular function | riboflavin kinase activity |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0005524 | Molecular function | ATP binding |
Gene name | RFK |
Protein name | Riboflavin kinase (EC 2.7.1.26) (ATP:riboflavin 5'-phosphotransferase) (Flavokinase) riboflavin kinase (EC 2.7.1.26) |
Synonyms | |
Description | FUNCTION: Catalyzes the phosphorylation of riboflavin (vitamin B2) to form flavin-mononucleotide (FMN), hence rate-limiting enzyme in the synthesis of FAD. Essential for TNF-induced reactive oxygen species (ROS) production. Through its interaction with both TNFRSF1A and CYBA, physically and functionally couples TNFRSF1A to NADPH oxidase. TNF-activation of RFK may enhance the incorporation of FAD in NADPH oxidase, a critical step for the assembly and activation of NADPH oxidase. . |
Accessions | ENST00000490113.1 H7C4G0 Q969G6 ENST00000376736.6 |